Document Detail

Type I interferon resistance in a colorectal cancer cell line is associated with a more aggressive phenotype in vivo.
Jump to Full Text
MedLine Citation:
PMID:  1558789     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
A type I interferon resistant variant (beta-MIP101) of the poorly differentiated human colon cancer cell MIP101 has a more aggressive phenotype in vivo in the nude mouse. Subcutaneous tumours grew at twice the rate of MIP101, but with similar morphology. beta-MIP101 also produced liver metastases at a higher frequency. beta-MIP101 tumours were diploid while MIP101 tumours were aneuploid. Both cell lines had doubling times of approximately 25 h in vitro.
Authors:
C A Toth; P Thomas
Related Documents :
8683659 - Schwann cell differentiation of modified myoepithelial cells within adenoid cystic carc...
10854139 - New chemotherapeutics in malignant mesothelioma: effects on cell growth and il-6 produc...
2448439 - Nucleolar organizer regions in small cell tumours of childhood.
3874329 - The antitumour effect of doxycycline on a t-cell leukaemia in the rat.
9808429 - Merkel cell differentiation in trichoblastoma.
1422189 - A possible role for cysteine proteinase and its inhibitors in motility of malignant mel...
6194249 - Antiviral, anticellular and enzyme-inducing activities of interferons in rd-114 cells.
9353059 - Utilization of similar mechanisms by legionella pneumophila to parasitize two evolution...
2463079 - Gap-junctional intercellular communication in epidermal cell lines from selected stages...
Publication Detail:
Type:  Journal Article; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  British journal of cancer     Volume:  65     ISSN:  0007-0920     ISO Abbreviation:  Br. J. Cancer     Publication Date:  1992 Mar 
Date Detail:
Created Date:  1992-05-12     Completed Date:  1992-05-12     Revised Date:  2010-09-07    
Medline Journal Info:
Nlm Unique ID:  0370635     Medline TA:  Br J Cancer     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  365-8     Citation Subset:  IM    
Affiliation:
Laboratory of Cancer Biology, New England Deaconess Hospital, Harvard Medical School, Boston, Massachusetts 02115.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Cell Division / drug effects
Cell Line
Colonic Neoplasms / drug therapy*,  genetics
Dose-Response Relationship, Drug
Drug Resistance
Flow Cytometry
Humans
Interferon Type I / therapeutic use*
Interferon-alpha / therapeutic use
Interferon-beta / metabolism,  therapeutic use
Interferon-gamma / therapeutic use
Liver Neoplasms / secondary
Mice
Mice, Nude
Neoplasm Transplantation
Ploidies
Recombinant Proteins / therapeutic use
Grant Support
ID/Acronym/Agency:
CA44583/CA/NCI NIH HHS; CA44704/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Interferon Type I; 0/Interferon-alpha; 0/Recombinant Proteins; 77238-31-4/Interferon-beta; 82115-62-6/Interferon-gamma
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): Br J Cancer
ISSN: 0007-0920
ISSN: 1532-1827
Article Information
Download PDF

Print publication date: Month: 3 Year: 1992
Volume: 65 Issue: 3
First Page: 365 Last Page: 368
ID: 1977610
PubMed Id: 1558789

Type I interferon resistance in a colorectal cancer cell line is associated with a more aggressive phenotype in vivo.
C. A. Toth
P. Thomas
Laboratory of Cancer Biology, New England Deaconess Hospital, Harvard Medical School, Boston, Massachusetts 02115.



Article Categories:
  • Research Article


Previous Document:  In vitro activity of the novel indoloquinone EO-9 and the influence of pH on cytotoxicity.
Next Document:  Enhanced 5-fluorouracil cytotoxicity and elevated 5-fluoronucleotides in the rat Walker carcinosarco...